Cargando…

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease

OBJECTIVE: The primary study objective of this retrospective academic memory clinic-based observational longitudinal study was to investigate the prognostic value of a cerebrospinal fluid (CSF)-based ATN classification for subsequent cognitive decline during the 3 years following lumbar puncture in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delmotte, Koen, Schaeverbeke, Jolien, Poesen, Koen, Vandenberghe, Rik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059197/ https://www.ncbi.nlm.nih.gov/pubmed/33879243 http://dx.doi.org/10.1186/s13195-021-00817-4

Ejemplares similares

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
por: Adamczuk, Katarzyna, et al.
Publicado: (2015)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
por: Luckett, Emma S., et al.
Publicado: (2022)

Longitudinal changes in (18)F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
por: Luckett, Emma S., et al.
Publicado: (2023)

Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?
por: Gauthier, S., et al.
Publicado: (2018)

Amnestic MCI Patients’ Perspectives toward Disclosure of Amyloid PET Results in a Research Context
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2017)

Amnestic MCI patients’ experiences after disclosure of their amyloid PET result in a research context
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2017)

From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting
por: Vanderschaeghe, Gwendolien, et al.
Publicado: (2018)

Changes in the language system as amyloid-β accumulates
por: Reinartz, Mariska, et al.
Publicado: (2021)

Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
por: Luckett, Emma S., et al.
Publicado: (2023)

Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
por: Duong, Michael Tran, et al.
Publicado: (2022)

Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
por: Iaccarino, Leonardo, et al.
Publicado: (2017)

Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease()
por: Vandenberghe, Rik, et al.
Publicado: (2013)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Classification of (18)F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth
por: Reinartz, Mariska, et al.
Publicado: (2022)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Serum neurofilament heavy chains as early marker of motor neuron degeneration
por: De Schaepdryver, Maxim, et al.
Publicado: (2019)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Pathway Analysis for Plasma β-Amyloid, Tau and Neurofilament Light (ATN) in World Trade Center Responders at Midlife
por: Kritikos, Minos, et al.
Publicado: (2020)

Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration
por: Gijs, Marlies, et al.
Publicado: (2021)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium
por: Xie, Zhongcong, et al.
Publicado: (2014)

Lack of association between bridging integrator 1 (BIN1) rs744373 polymorphism and tau‐PET load in cognitively intact older adults
por: Schaeverbeke, Jolien, et al.
Publicado: (2022)

Structural Connectivity Alterations Along the Alzheimer’s Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau
por: Tucholka, Alan, et al.
Publicado: (2018)

Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer’s disease
por: Xue, Mei, et al.
Publicado: (2020)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
por: Turk, Katherine W., et al.
Publicado: (2022)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Exploring the ATN classification system using brain morphology
por: Heinzinger, Nils, et al.
Publicado: (2023)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
por: Bartl, Michael, et al.
Publicado: (2021)

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
por: Voyle, Nicola, et al.
Publicado: (2016)

β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population
por: Rosenberg, Anna, et al.
Publicado: (2022)

PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
por: Koychev, Ivan, et al.
Publicado: (2017)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

Surgical Outcomes of Myopic Foveoschisis According to the ATN Classification System
por: Fang, Dong, et al.
Publicado: (2022)

ATN profile classification across two independent prospective cohorts
por: Peretti, Débora E., et al.
Publicado: (2023)

Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals
por: Paterson, R W, et al.
Publicado: (2014)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_218hll06bt79n6ecmq8qmobkfo